報價延遲最少15分鐘:2024/06/13 10:31 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
146.3 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-15.60/-3.78
|
|
企業價值
57.83B
|
| 資產負債 |
|
每股賬面淨值
33.44
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
6.75B
|
|
每股收益
23.72
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/06/13 10:31 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |